IQV vs NVAX · P/E 23, rev $16.31B vs P/E 2.5, rev $196.2M
IQVIA Holdings Inc (IQV) versus Novavax Inc (NVAX) — a side-by-side from cached financials, not a winner call.
IQVIA Holdings Inc (IQV) is a diagnostics & research company listed on US.
Novavax Inc (NVAX) is a biotechnology company listed on US.
Latest reported IQV revenue for 2025-12-31 was $16.31B. Net income was $1.36B. Revenue was up 5.9% from 2024-12-31 to 2025-12-31. IQV currently screens at market cap $30.62B and trailing P/E 22.8.
Latest reported NVAX revenue for 2026-06-30 was $196.2M. Net income was -$62.9M. Revenue was up 40.6% from 2026-03-31 to 2026-06-30. NVAX currently screens at market cap $1.09B and trailing P/E 2.5.
IQV currently screens at market cap $30.62B and trailing P/E 22.8. NVAX currently screens at market cap $1.09B and trailing P/E 2.5.
Not investment advice. Open the IQV and NVAX stock pages for the full models.
Not investment advice.